Published Paper Details:

This review explores the current scientific advancements and future potential of 3D bioprinting in the pharmaceutical sector. Conducted in accordance with PRISMA guidelines, this review draws data from PubMed, Scopus, Google Scholar, and ScienceDirect using keywords such as 3D bioprinting, drug development, personalized medicine, pharmaceutical applications, and drug testing. The paper highlights the diverse roles of bioprinting in pharmaceuticals, with a particular emphasis on drug discovery, personalized medicine, and most notably, drug screening and testing. Recent technological advancements have enabled the creation of patient-specific drug testing platforms and targeted delivery systems. Notably, bioprinting allows the precise placement of cells and biomaterials to develop miniaturized organ models (organoids) and Organ-on-a-Chip systems, which may reduce reliance on animal testing. This approach enhances prediction accuracy in early-stage drug trials and accelerates the path to market. Despite its transformative promise, 3D bioprinting still faces critical challenges, including issues related to vascularization, material limitations, standardization, and scalability. Nonetheless, the technology continues to evolve, with significant implications for tissue engineering, drug delivery systems, and regenerative medicine. This review provides an overview of current applications, critical limitations, and future prospects of 3D bioprinting in pharmaceutical research and development.